Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Cybin Inc.
Industry Sector: HealthTechnology
CEO: Douglas L. Drysdale
Number Of Employees: N/A
Enterprise Value: N/A
PE Ratio: -1.64
Exchange/Ticker 1: NYSE-A:CYBN
Exchange/Ticker 2: NEO:CYBN
Latest Market Cap: $131,684,696
BioCentury | Aug 20, 2024
Politics, Policy & Law
Drug pricing, psychedelic setback & Back to School preview — a BioCentury podcast
Medicare drug prices revealed. Avoiding Lykos’ lapses. Translating from target to product
BioCentury | Aug 17, 2024
Product Development
How the next psychedelics companies believe they can avoid Lykos’ fate
Functional unblinding, expectation bias are surmountable hurdles
BioCentury | Jun 12, 2024
Management Tracks
Former Fusion CFO Crowley joins Centessa
Weinhoff becomes CBO. Plus: QurAlis pads C-suite and updates from PepGen, C4 and more
BioCentury | Mar 15, 2024
Finance
Public equity report: PIPEs for Lexicon, Cybin, Regulus, Lexeo
Companies raise cash as they eye paths forward in diabetes, depression, kidney disease and Friedreich ataxia
BioCentury | Feb 13, 2024
Product Development
ADCs, psychedelics & biotech IPOs: BioCentury’s latest podcast
Plus: Gilead’s $4.3B takeout of CymaBay
BioCentury | Feb 6, 2024
Product Development
Bringing psychedelics into the drug development fold
Second-generation psychedelics are being tested in more conventional clinical trials, and starting to yield impressive efficacy
BioCentury | Nov 30, 2023
Finance
Nov. 30 Quick Takes: Xenon follows depression data with $300M raise
Plus: Latest data for Merck’s TIGIT blocker vibostolimab and updates for AbbVie’s Teliso-V, Fortrea-Acelyrin, Cybin’s psilocybin therapy and Intermountain Health spinout Culmination Bio
BioCentury | Aug 19, 2023
Product Development
Psychedelic pipeline moves toward proof of concept
But the field’s biggest question won’t be answered for a while: whether it’s possible to take the psychedelic out of psychedelics
BioCentury | Oct 5, 2021
Management Tracks
Bernstein becomes CMO at BioMarin
Plus: Novavax, TPG, Noema, Syndax, Prothena, Annexon, ProQR and more
Items per page:
1 - 9 of 9